ABVC · Nasdaq · ·
Next earnings: October 30, 2026
$1.050.0%Sep 29 close
Abvc Biopharma, Inc. is scheduled to report next on October 30, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toJun 30, 2024 | Change |
|---|---|---|---|
| Total Revenue | -$500K | $117.1K | -526.79% |
| Profit | -$736.9K | -$2.3M | +67.35% |
| Profit per share | -$0.03 | -$0.13 | +76.92% |
| Free Cash Flow | -$430.5K | -$3.1M | +86.06% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus ® ) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company’s network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Abvc Biopharma, Inc.’s Item 2.02 8-K filed March 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Abvc Biopharma, Inc. has no earnings call transcript available.